|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Fumapharm_AG
gptkb:Idec_Pharmaceuticals
|
|
gptkbp:awards
|
Best Places to Work
Top_Employer_Europe
|
|
gptkbp:CEO
|
gptkb:Michel_Vounatsos
|
|
gptkbp:clinicalTrials
|
Completed
Ongoing
Phase 1
Phase 2
Phase 3
|
|
gptkbp:collaborations
|
Academic Institutions
Research Organizations
|
|
gptkbp:employees
|
Over 7,000
|
|
gptkbp:financialPerformance
|
Market Capitalization
Revenue Growth
Profitability
Stock Performance
Investment in R&D
|
|
gptkbp:focusArea
|
Neuroscience
Neurology
|
|
gptkbp:founded
|
2003
|
|
gptkbp:headquarters
|
gptkb:Zug,_Switzerland
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Biogen Idec Europe GmbH
|
|
gptkbp:industry
|
Biotechnology
|
|
gptkbp:market
|
Global
|
|
gptkbp:parentCompany
|
gptkb:Biogen_Inc.
|
|
gptkbp:partnerships
|
gptkb:Samsung_Bioepis
|
|
gptkbp:philanthropy
|
gptkb:Biogen_Foundation
|
|
gptkbp:products
|
gptkb:Tecfidera
gptkb:Avonex
gptkb:Tysabri
|
|
gptkbp:region
|
Europe
|
|
gptkbp:regulatoryCompliance
|
EMA_Approved
FDA_Approved
Health_Canada_Approved
TGA_Approved
|
|
gptkbp:researchFocus
|
gptkb:Amyotrophic_Lateral_Sclerosis
Multiple Sclerosis
Parkinson's Disease
Alzheimer's Disease
Spinal Muscular Atrophy
|
|
gptkbp:services
|
Commercialization
Research_and_Development
|
|
gptkbp:subsidiary
|
gptkb:Biogen_Inc.
|
|
gptkbp:sustainability
|
Community Engagement
Diversity and Inclusion
Ethical Business Practices
Environmental Initiatives
Employee Wellbeing
|
|
gptkbp:website
|
www.biogen.com
|